| Previous Close | 104.35 |
| Open | 104.34 |
| Bid | 102.42 x 900 |
| Ask | 103.80 x 900 |
| Day's Range | 102.92 - 104.78 |
| 52 Week Range | 72.13 - 122.15 |
| Volume | 4,904,940 |
| Avg. Volume | 4,812,417 |
| Market Cap | 138.428B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 31.59 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.32 (2.22%) |
| Ex-Dividend Date | Sep. 24, 2020 |
| 1y Target Est | N/A |
- CNW Group
Medtronic Canada Recognized as One of the Best Workplaces™ in Healthcare for the Second Consecutive Year
BRAMPTON, ON, Sept. 15, 2020 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — one of the world's largest medical technology, services, and solutions companies — announced today that it has been recognized as one of the Best Workplaces in Healthcare for the second consecutive year.
- CNW Group
Medtronic CEO Geoff Martha to Speak at Morgan Stanley Global Healthcare Conference
DUBLIN, Sept. 11, 2020 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020.
- CNW Group
Medtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly
* PRODIGY Study Provides First Validated Risk Prediction Tool to Guide Continuous Monitoring for Opioid-Induced Respiratory Depression (OIRD) * OIRD Occurred in 46% of Patients Studied * Patients with Respiratory Depression Are 37% More Likely to Experience an Adverse Event and Require Longer Hospital StaysDUBLIN, Sept. Importantly, conclusions from the study data enabled the development of the PRODIGY Risk Score, an easy-to-use risk prediction tool to identify patients at high risk of respiratory depression who would benefit from continuous monitoring with capnography and pulse oximetry.
